{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T03:26:43Z","timestamp":1769052403857,"version":"3.49.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T00:00:00Z","timestamp":1687910400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T00:00:00Z","timestamp":1687910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Zhejiang Provincial Medical Health Science and Technology Project","award":["No. 2022KY107"],"award-info":[{"award-number":["No. 2022KY107"]}]},{"name":"Hospital Pharmacy Special Project of Zhejiang Pharmaceutical Association","award":["No. 2021ZYY19"],"award-info":[{"award-number":["No. 2021ZYY19"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s00280-023-04559-y","type":"journal-article","created":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T06:02:19Z","timestamp":1687932139000},"page":"181-192","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Population pharmacokinetics and toxicity correlation analysis of free and liposome-encapsulated doxorubicin in Chinese patients with advanced breast cancer"],"prefix":"10.1007","volume":"92","author":[{"given":"Gaoqi","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dihong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaoneng","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Like","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junfeng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Shu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiying","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenxiu","family":"Xin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinghui","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1187-4195","authenticated-orcid":false,"given":"Luo","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,28]]},"reference":[{"key":"4559_CR1","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.drup.2016.10.003","volume":"29","author":"AA Gabizon","year":"2016","unstructured":"Gabizon AA, Patil Y, La-Beck NM (2016) New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy. Drug Resist Updat 29:90\u2013106. https:\/\/doi.org\/10.1016\/j.drup.2016.10.003","journal-title":"Drug Resist Updat"},{"key":"4559_CR2","doi-asserted-by":"publisher","first-page":"120117","DOI":"10.1016\/j.ijpharm.2020.120117","volume":"593","author":"V Makwana","year":"2021","unstructured":"Makwana V, Karanjia J, Haselhorst T, Anoopkumar-Dukie S, Rudrawar S (2021) Liposomal doxorubicin as targeted delivery platform: current trends in surface functionalization. Int J Pharm 593:120117. https:\/\/doi.org\/10.1016\/j.ijpharm.2020.120117","journal-title":"Int J Pharm"},{"issue":"1","key":"4559_CR3","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13048-022-01029-6","volume":"15","author":"XR Li","year":"2022","unstructured":"Li XR, Cheng XH, Zhang GN, Wang XX, Huang JM (2022) Cardiac safety analysis of first-line chemotherapy drug pegylated liposomal doxorubicin in ovarian cancer. J Ovarian Res 15(1):96. https:\/\/doi.org\/10.1186\/s13048-022-01029-6","journal-title":"J Ovarian Res"},{"issue":"18","key":"4559_CR4","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.2165\/11207510-000000000-00000","volume":"71","author":"ST Duggan","year":"2011","unstructured":"Duggan ST, Keating GM (2011) Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi\u2019s sarcoma. Drugs 71(18):2531\u20132558. https:\/\/doi.org\/10.2165\/11207510-000000000-00000","journal-title":"Drugs"},{"issue":"5","key":"4559_CR5","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s40259-013-0070-1","volume":"27","author":"KA Lyseng-Williamson","year":"2013","unstructured":"Lyseng-Williamson KA, Duggan ST, Keating GM (2013) Pegylated liposomal doxorubicin: a guide to its use in various malignancies. BioDrugs 27(5):533\u2013540. https:\/\/doi.org\/10.1007\/s40259-013-0070-1","journal-title":"BioDrugs"},{"issue":"2","key":"4559_CR6","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/0005-2736(93)90105-9","volume":"1151","author":"G Haran","year":"1993","unstructured":"Haran G, Cohen R, Bar LK, Barenholz Y (1993) Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta 1151(2):201\u2013215. https:\/\/doi.org\/10.1016\/0005-2736(93)90105-9","journal-title":"Biochim Biophys Acta"},{"issue":"6","key":"4559_CR7","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1517\/17425255.2011.570330","volume":"7","author":"M Morotti","year":"2011","unstructured":"Morotti M, Valenzano Menada M, Venturini PL, Ferrero S (2011) Pharmacokinetic and toxicity considerations for the use of anthracyclines in ovarian cancer treatment. Expert Opin Drug Metab Toxicol 7(6):707\u2013720. https:\/\/doi.org\/10.1517\/17425255.2011.570330","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"Suppl 4","key":"4559_CR8","doi-asserted-by":"publisher","first-page":"30","DOI":"10.2165\/00003495-199700544-00007","volume":"54","author":"DS Alberts","year":"1997","unstructured":"Alberts DS, Garcia DJ (1997) Safety aspects of pegylated liposomal doxorubicin in patients with cancer. Drugs 54(Suppl 4):30\u201335. https:\/\/doi.org\/10.2165\/00003495-199700544-00007","journal-title":"Drugs"},{"issue":"10","key":"4559_CR9","doi-asserted-by":"publisher","first-page":"940","DOI":"10.3390\/pharmaceutics12100940","volume":"12","author":"S Filip","year":"2020","unstructured":"Filip S, Kube\u010dek O, \u0160pa\u010dek J, L\u00e1nsk\u00e1 M, Bl\u00e1ha M (2020) Therapeutic apheresis, circulating PLD, and mucocutaneous toxicity: our clinical experience through four years. Pharmaceutics 12(10):940. https:\/\/doi.org\/10.3390\/pharmaceutics12100940","journal-title":"Pharmaceutics"},{"issue":"7","key":"4559_CR10","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1093\/annonc\/mdl477","volume":"18","author":"D Lorusso","year":"2007","unstructured":"Lorusso D, Di Stefano A, Carone V, Fagotti A, Pisconti S, Scambia G (2007) Pegylated liposomal doxorubicin-related palmar\u2013plantar erythrodysesthesia (\u201chand\u2013foot\u201d syndrome). Ann Oncol 18(7):1159\u20131164. https:\/\/doi.org\/10.1093\/annonc\/mdl477","journal-title":"Ann Oncol"},{"issue":"2","key":"4559_CR11","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1159\/000093005","volume":"70","author":"SE Al-Batran","year":"2006","unstructured":"Al-Batran SE, Meerpohl HG, von Minckwitz G, Atmaca A, Kleeberg U, Harbeck N, Lerbs W, Hecker D, Sehouli J, Knuth A, Jager E (2006) Reduced incidence of severe palmar\u2013plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg\/m2 every 4 weeks in previously treated patients with metastatic breast cancer. Oncology 70(2):141\u2013146. https:\/\/doi.org\/10.1159\/000093005","journal-title":"Oncology"},{"issue":"3","key":"4559_CR12","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s00280-014-2514-9","volume":"74","author":"MJ Boers-Sonderen","year":"2014","unstructured":"Boers-Sonderen MJ, van Herpen CM, van der Graaf WT, Desar IM, van der Logt MG, de Beer YM, Ottevanger PB, van Erp NP (2014) Correlation of toxicity and efficacy with pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) (Caelyx\u00ae). Cancer Chemother Pharmacol 74(3):457\u2013463. https:\/\/doi.org\/10.1007\/s00280-014-2514-9","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"4559_CR13","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ejon.2006.10.004","volume":"11","author":"JD Webster-Gandy","year":"2007","unstructured":"Webster-Gandy JD, How C, Harrold K (2007) Palmar\u2013plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre. Eur J Oncol Nurs 11(3):238\u2013246. https:\/\/doi.org\/10.1016\/j.ejon.2006.10.004","journal-title":"Eur J Oncol Nurs"},{"issue":"4","key":"4559_CR14","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.ejps.2011.09.006","volume":"45","author":"A Gabizon","year":"2012","unstructured":"Gabizon A, Shmeeda H, Grenader T (2012) Pharmacological basis of pegylated liposomal doxorubicin: impact on cancer therapy. Eur J Pharm Sci 45(4):388\u2013398. https:\/\/doi.org\/10.1016\/j.ejps.2011.09.006","journal-title":"Eur J Pharm Sci"},{"issue":"2","key":"4559_CR15","doi-asserted-by":"publisher","first-page":"1000361","DOI":"10.4172\/2157-7439.1000361","volume":"7","author":"SM Ali","year":"2016","unstructured":"Ali SM, Sheikh S, Ahmad A, Ahmad MU, Chen P, Paithankar M, Choudhury K, Makadia RD, Kumar A, Velavan K, Satheesh CT, Singh JK, Mamillapalli G, Saptarishi D, Kale P, Patel R, Barkate HV, Ahmad I (2016) Bioequivalence study of pegylated doxorubicin hydrochloride liposome (PEGADRIA) and DOXIL\u00ae in ovarian cancer patients: physicochemical characterization and pre-clinical studies. J Nanomed Nanotechnol 7(2):1000361. https:\/\/doi.org\/10.4172\/2157-7439.1000361","journal-title":"J Nanomed Nanotechnol"},{"issue":"9","key":"4559_CR16","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1002\/psp4.12838","volume":"11","author":"RJ Svensson","year":"2022","unstructured":"Svensson RJ, Jonsson EN (2022) Efficient and relevant stepwise covariate model building for pharmacometrics. CPT Pharmacomet Syst Pharmacol 11(9):1210\u20131222. https:\/\/doi.org\/10.1002\/psp4.12838","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"6","key":"4559_CR17","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1002\/psp4.12790","volume":"11","author":"EN Jonsson","year":"2022","unstructured":"Jonsson EN, Nyberg J (2022) A quantitative approach to the choice of number of samples for percentile estimation in bootstrap and visual predictive check analyses. CPT Pharmacomet Syst Pharmacol 11(6):673\u2013686. https:\/\/doi.org\/10.1002\/psp4.12790","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"5","key":"4559_CR18","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1023\/a:1012299115260","volume":"28","author":"SL Beal","year":"2001","unstructured":"Beal SL (2001) Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 28(5):481. https:\/\/doi.org\/10.1023\/a:1012299115260","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"4559_CR19","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/978-3-030-43032-0_15","volume":"1257","author":"A Bhagat","year":"2020","unstructured":"Bhagat A, Kleinerman ES (2020) Anthracycline-induced cardiotoxicity: causes, mechanisms, and prevention. Adv Exp Med Biol 1257:181\u2013192. https:\/\/doi.org\/10.1007\/978-3-030-43032-0_15","journal-title":"Adv Exp Med Biol"},{"issue":"4","key":"4559_CR20","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1007\/s12012-022-09721-1","volume":"22","author":"M Sheibani","year":"2022","unstructured":"Sheibani M, Azizi Y, Shayan M, Nezamoleslami S, Eslami F, Farjoo MH, Dehpour AR (2022) Doxorubicin-induced cardiotoxicity: an overview on pre-clinical therapeutic approaches. Cardiovasc Toxicol 22(4):292\u2013310. https:\/\/doi.org\/10.1007\/s12012-022-09721-1","journal-title":"Cardiovasc Toxicol"},{"issue":"6","key":"4559_CR21","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1093\/annonc\/mdf157","volume":"13","author":"A Hamilton","year":"2002","unstructured":"Hamilton A, Biganzoli L, Coleman R, Mauriac L, Hennebert P, Awada A, Nooij M, Beex L, Piccart M, Van Hoorebeeck I, Bruning P, de Valeriola D (2002) EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European Organization for Research and Treatment of Cancer. Ann Oncol 13(6):910\u2013918. https:\/\/doi.org\/10.1093\/annonc\/mdf157","journal-title":"Ann Oncol"},{"issue":"5","key":"4559_CR22","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/j.1365-2710.2009.01128.x","volume":"35","author":"L Xu","year":"2010","unstructured":"Xu L, Wang W, Sheng YC, Zheng QS (2010) Pharmacokinetics and its relation to toxicity of pegylated-liposomal doxorubicin in Chinese patients with breast tumours. J Clin Pharm Ther 35(5):593\u2013601. https:\/\/doi.org\/10.1111\/j.1365-2710.2009.01128.x","journal-title":"J Clin Pharm Ther"},{"issue":"2","key":"4559_CR23","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s00280-019-03976-2","volume":"85","author":"O Kube\u010dek","year":"2020","unstructured":"Kube\u010dek O, Mart\u00ednkov\u00e1 J, Chl\u00e1dek J, Bl\u00e1ha M, Mal\u00e1kov\u00e1 J, Hodek M, \u0160pa\u010dek J, Filip S (2020) Plasmafiltration as an effective method in the removal of circulating pegylated liposomal doxorubicin (PLD) and the reduction of mucocutaneous toxicity during the treatment of advanced platinum-resistant ovarian cancer. Cancer Chemother Pharmacol 85(2):353\u2013365. https:\/\/doi.org\/10.1007\/s00280-019-03976-2","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"4559_CR24","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/s11095-018-2387-4","volume":"35","author":"LF Hsu","year":"2018","unstructured":"Hsu LF (2018) Investigation of the discriminatory ability of pharmacokinetic metrics for the bioequivalence assessment of PEGylated liposomal doxorubicin. Pharm Res 35(5):106. https:\/\/doi.org\/10.1007\/s11095-018-2387-4","journal-title":"Pharm Res"},{"issue":"1","key":"4559_CR25","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1186\/s12885-021-09050-6","volume":"21","author":"J Zhang","year":"2021","unstructured":"Zhang J, Jiang H, Zhang J, Bao G, Zhang G, Wang H, Wang X (2021) Effectiveness and safety of pegylated liposomal doxorubicin versus epirubicin as neoadjuvant or adjuvant chemotherapy for breast cancer: a real-world study. BMC Cancer 21(1):1301. https:\/\/doi.org\/10.1186\/s12885-021-09050-6","journal-title":"BMC Cancer"},{"issue":"10","key":"4559_CR26","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1002\/cncr.20207","volume":"100","author":"M Theodoulou","year":"2004","unstructured":"Theodoulou M, Hudis C (2004) Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin? Cancer 100(10):2052\u20132063. https:\/\/doi.org\/10.1002\/cncr.20207","journal-title":"Cancer"},{"issue":"5","key":"4559_CR27","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1002\/1097-0142(20000901)89:5<1037::aid-cncr13>3.0.co;2-z","volume":"89","author":"O Lyass","year":"2000","unstructured":"Lyass O, Uziely B, Ben-Yosef R, Tzemach D, Heshing NI, Lotem M, Brufman G, Gabizon A (2000) Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 89(5):1037\u20131047. https:\/\/doi.org\/10.1002\/1097-0142(20000901)89:5%3c1037::aid-cncr13%3e3.0.co;2-z","journal-title":"Cancer"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04559-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-023-04559-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04559-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T10:02:23Z","timestamp":1690020143000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-023-04559-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,28]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["4559"],"URL":"https:\/\/doi.org\/10.1007\/s00280-023-04559-y","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,28]]},"assertion":[{"value":"4 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The studies involving human participants were reviewed and approved by the Ethics Committee of the Fourth Hospital of Hebei Medical University, Affiliated Hospital of Hebei University and Henan Cancer Hospital. The patients provided their written informed consent to participate in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}